MSCs, which contribute to the bone and bone marrow, are able to differentiate into osteoblasts and form bone, as well as contribute to the hematopoietic environment. This capability might be used in cell therapy to enhance recovery of the marrow after high-dose chemotherapy, and to enhance bone formation in the treatment of osteoporosis syndromes of children and adults. To evaluate the safety and toxicity of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following bone marrow transplantation in patients with some form of osteodysplasia.
Eligibility Has an appropriate genetic disorder.
Has had an allogeneic bone marrow transplant, and currently maintains complete or mixed hematopoietic chimerism. Must be less than or equal to 18 kg body weight. Donor from the allogeneic bone marrow transplant must be willing and able to provide 50 ml bone marrow. No infection Not participating in any other investigational study that could potentially confound the interpretation of the safety parameters being investigated in this study.